NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

多形性膠質母細胞瘤:現在的市場機會和今後的預測,流行病學研究,市場動態,開發平台分析,風險調整淨現值(r-NPV分析)

Glioblastoma Multiforme - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis

出版商 GervanoRA Data Services LLP 商品編碼 1024216
出版日期 內容資訊 英文 222 Pages
商品交期: 3-5個工作天內
價格
多形性膠質母細胞瘤:現在的市場機會和今後的預測,流行病學研究,市場動態,開發平台分析,風險調整淨現值(r-NPV分析) Glioblastoma Multiforme - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis
出版日期: 2021年08月11日內容資訊: 英文 222 Pages
簡介

本報告提供多形性膠質母細胞瘤市場調查,彙整市場及疾病概要,市場趨勢,流行病學調查,進行中的研究開發概要,新加入企業的市場佔有率預測及價格策略,風險調整淨現值(r-NPV)分析,開發階段·給藥途徑·作用機制·藥物類別·分子類型·標的·適應症·企業類型·各地區的開發平台(管線)的概述及比較分析,未滿足需求,開發平台藥物的專利趨勢,到2030年前的市場預測,治療領域的交易趨勢等資料。

目錄

第1章 簡介

第2章 摘要整理

第3章 疾病概要與流行病學研究

第4章 多形性膠質母細胞瘤的市場規模的變化與預測(2020年∼2030年)

第5章 開發平台(管線)的洞察和基準預測

第6章 多形性膠質母細胞瘤的交易趨勢

第7章 多形性膠質母細胞瘤開發平台藥物的專利比較分析

第8章 風險調整淨現值(r-NPV)分析

第9章 競爭機會的評估

目錄
Product Code: GERPH518

GervanoRA's pipeline analysis and opportunity assessment report "Glioblastoma Multiforme - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis" analysed and assessed Glioblastoma Multiforme pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Glioblastoma Multiforme drugs industry.

The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the Glioblastoma Multiforme area. The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in Glioblastoma Multiforme drugs industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Stage of development, Pipeline Analytics by Route of Administration, Pipeline Analytics by Geography, Pipeline Analytics by Mechanism of Action, Pipeline Analytics by Drug Class, Pipeline Analytics by Molecule Type, Pipeline Analytics by Target and Pipeline Analytics by Company Type.

The report delivers an in-depth understanding of the Glioblastoma Multiforme historical and forecasted epidemiology based market trends Worldwide, the United States, EU9 (Poland, Russia, Switzerland, Sweden, Italy, Germany, Austria, France, and United Kingdom) and China. A detailed analytics on the Current Glioblastoma Multiforme Market (2020) and the Forecasted Glioblastoma Multiforme Market until the year 2035 for the regions have been provided.

Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the Emerging companies in the domain based on In-Licensing opportunities, Out-Licensing opportunities, Corporate Partnering opportunities and funding opportunities. The report even aimed to conduct the Risk-Adjusted Net Present Value (RNPV) Analysis with its Excel based r-NPV analysis model to help companies in licensing negotiations, technology valuations and pipeline asset valuation and establishing the value for licensing deal. It also aims to provide the sales potential of the drugs along with the new drugs pricing and pricing strategies.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Epidemiological Studies - Historical Trends and Probabilistic Epidemiology Forecast
  • Epidemiology Based Market Estimations - Current Market Value and Market Forecast
  • Plotting of the Anticipated Market Share for the New Entrants
  • Pricing Strategies of New Entrants Supported Through KOL Insights
  • Risk-Adjusted Net Present Value (RNPV) Analysis
  • Comparative Pipeline Insights and Benchmarking Snapshots by HSD, Geography, RoA, Drug Class, MoA, Molecule Target, Molecule Type
  • Unmet Needs and Opportunities
  • Comparative Patent Analytics of Glioblastoma Multiforme Pipeline Drugs
  • Competitive Opportunity Assessments of the Active Players in the Glioblastoma Multiforme Therapeutic Space by Partnering, Licensing and Funding Opportunities
  • Deals Activities of Glioblastoma Multiforme Therapeutic Space

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: DISEASE OVERVIEW AND EPIDEMIOLOGICAL STUDIES

CHAPTER 4: GLIOBLASTOMA MULTIFORME CURRENT MARKET VALUE AND FORECAST 2020 - 2030

CHAPTER 5: PIPELINE INSIGHTS AND BENCHMARKING OUTLOOK

CHAPTER 6: DEALS ACTIVITIES OF GLIOBLASTOMA MULTIFORME COMPETITIVE SPACE

CHAPTER 7: COMPARATIVE PATENT ANALYTICS OF GLIOBLASTOMA MULTIFORME PIPELINE DRUGS

CHAPTER 8: RISK-ADJUSTED NET PRESENT VALUE (R-NPV) ANALYSIS

CHAPTER 9: COMPETITIVE OPPORTUNITY ASSESSMENTS

LIST OF TABLES

  • TABLE 1: REPORT HIGHLIGHTS IN NUMERICALS
  • TABLE 2: APPROVED DRUGS AVAILABLE FOR THE TREATMENT OF GBM
  • TABLE 3: PREVALENCE OF GBM IN 2010 AND 2035 WORLDWIDE ALONG WITH SPECIFIC COUNTRIES
  • TABLE 4: PREVALENCE RATE OF GBM IN 2010 AND 2035 WORLDWIDE ALONG WITH SPECIFIC COUNTRIES
  • TABLE 5: INCIDENCE RATE OF GBM IN 2010 AND 2035 WORLDWIDE ALONG WITH SPECIFIC COUNTRIES
  • TABLE 6: INCIDENCE OF GBM IN 2010 AND 2035 WORLDWIDE ALONG WITH SPECIFIC COUNTRIES
  • TABLE 7: LIST OF AVAILABLE DRUGS AND THEIR RESPECTIVE AVERAGE COST PER SINGLE PATIENT
  • TABLE 8: TEMOZOLOMIDE ANNUAL SALES FROM 2005 TO 2020
  • TABLE 9: AVASTIN ANNUAL SALES FROM 2010 TO 2020
  • TABLE 10: LIST OF NEW ENTRANTS CONSIDERED FOR FORECASTING THE GBM MARKET
  • TABLE 11: GBM CURRENT GLOBAL MARKET (2020) BY AVAILABLE DRUGS
  • TABLE 12: GBM GLOBAL MARKET FORECAST 2021-2035
  • TABLE 12A: COMPANION DIAGNOSTIC TESTS FOR GBM
  • TABLE 13: GBM GLOBAL MARKET IN 2021 BY AVAILABLE DRUGS
  • TABLE 14: GBM GLOBAL MARKET IN 2022 BY AVAILABLE DRUGS AND NEW ENTRANTS
  • TABLE 15: GBM GLOBAL MARKET IN 2023 BY AVAILABLE DRUGS AND NEW ENTRANTS
  • TABLE 16: GBM GLOBAL MARKET IN 2024 BY AVAILABLE DRUGS AND NEW ENTRANTS
  • TABLE 17: GBM GLOBAL MARKET IN 2025 BY AVAILABLE DRUGS AND NEW ENTRANTS
  • TABLE 18: GBM GLOBAL MARKET IN 2026 BY AVAILABLE DRUGS AND NEW ENTRANTS
  • TABLE 19: GBM GLOBAL MARKET IN 2027 BY AVAILABLE DRUGS AND NEW ENTRANTS
  • TABLE 20: GBM GLOBAL MARKET IN 2028 BY AVAILABLE DRUGS AND NEW ENTRANTS
  • TABLE 21: GBM GLOBAL MARKET IN 2029 BY AVAILABLE DRUGS AND NEW ENTRANTS
  • TABLE 22: GBM GLOBAL MARKET IN 2030 BY AVAILABLE DRUGS AND NEW ENTRANTS
  • TABLE 23: GBM GLOBAL MARKET IN 2031 BY AVAILABLE DRUGS AND NEW ENTRANTS
  • TABLE 24: GBM GLOBAL MARKET IN 2032 BY AVAILABLE DRUGS AND NEW ENTRANTS
  • TABLE 25: GBM GLOBAL MARKET IN 2033 BY AVAILABLE DRUGS AND NEW ENTRANTS
  • TABLE 26: GBM GLOBAL MARKET IN 2034 BY AVAILABLE DRUGS AND NEW ENTRANTS
  • TABLE 27: GBM GLOBAL MARKET IN 2035 BY AVAILABLE DRUGS AND NEW ENTRANTS
  • TABLE 28: GBM GLOBAL MARKET FORECAST - 2035 BY AVAILABLE DRUGS
  • TABLE 29: COMPARISON OF GBM MARKET VALUES GLOBAL VS USA (2020 - 2035) (M$)
  • TABLE 30: COMPARISON OF GBM MARKET VALUES GLOBAL VS POLAND (2020 - 2035) (M$)
  • TABLE 31: COMPARISON OF GBM MARKET VALUES GLOBAL VS RUSSIA (2020 - 2035) (M$)
  • TABLE 32: COMPARISON OF GBM MARKET VALUES GLOBAL VS SWITZERLAND (2020 - 2035) (M$)
  • TABLE 33: COMPARISON OF GBM MARKET VALUES GLOBAL VS SWEDEN (2020 - 2035) (M$)
  • TABLE 34: COMPARISON OF GBM MARKET VALUES GLOBAL VS ITALY (2020 - 2035) (M$)
  • TABLE 35: COMPARISON OF GBM MARKET VALUES GLOBAL VS GERMANY (2020 - 2035) (M$)
  • TABLE 36: COMPARISON OF GBM MARKET VALUES GLOBAL VS AUSTRIA (2020 - 2035) (M$)
  • TABLE 37: COMPARISON OF GBM MARKET VALUES GLOBAL VS FRANCE (2020 - 2035) (M$)
  • TABLE 38: COMPARISON OF GBM MARKET VALUES GLOBAL VS UNITED KINGDOM (2020 - 2035) (M$)
  • TABLE 39: COMPARISON OF GBM MARKET VALUES GLOBAL VS CHINA (2020 - 2035) (M$)
  • TABLE 40: PIPELINE DRUG CANDIDATES GRANTED WITH SPECIAL REGULATORY ALLOWANCES
  • TABLE 41: OTHER PIPELINE DRUG CANDIDATES GRANTED WITH ORPHAN DRUG DESIGNATION
  • TABLE 42: COLLABORATION DEALS IN GBM THERAPEUTIC AREA
  • TABLE 43: LICENSING DEALS IN GBM THERAPEUTIC AREA
  • TABLE 44: FINANCING DEALS IN GBM THERAPEUTIC AREA
  • TABLE 45: MERGER AND ACQUISITION DEALS IN GBM THERAPEUTIC AREA
  • TABLE 46: TOP DEALS UNDER COLLABORATION DEALS IN GBM THERAPEUTIC AREA
  • TABLE 47: TOP DEALS UNDER LICENSING DEALS IN GBM THERAPEUTIC AREA
  • TABLE 48: TOP DEALS UNDER FINANCING DEALS IN GBM THERAPEUTIC AREA
  • TABLE 49: TOP DEALS UNDER M&A DEALS IN GBM THERAPEUTIC AREA
  • TABLE 50: MAJOR PATENTS OF WPD101 ALONG WITH THEIR FILING, APPROVAL AND ANTICIPATED EXPIRY DATES
  • TABLE 51: LIST OF PIPELINE DRUGS WITH GRANTED SPECIAL REGULATORY PATENT ALLOWANCES COMPARED WITH WPD101
  • TABLE 52: PIPELINE DRUGS WITH GRANTED SPECIAL REGULATORY PATENT ALLOWANCES COMPARED WITH BERUBICIN
  • TABLE 53: SPECIAL REGULATORY ALLOWANCES GRANTED TO PRODUCTS IN COMPARISON TO WP1066
  • TABLE 54: SPECIAL REGULATORY ALLOWANCES GRANTED TO PRODUCTS IN COMPARISON TO WP1122
  • TABLE 55: FACTORS CONSIDERED FOR R-NPV ANALYSIS OF WPD101
  • TABLE 56: LIST OF NEW ENTRANTS COMPETING TO EACH OTHER TO OCCUPY THE MARKET POTENTIAL IN 2032
  • TABLE 57: FACTORS CONSIDERED FOR R-NPV ANALYSIS OF BERUBICIN
  • TABLE 58: LIST OF NEW ENTRANTS COMPETING TO EACH OTHER TO OCCUPY THE MARKET POTENTIAL IN 2031
  • TABLE 59: FACTORS CONSIDERED FOR R-NPV ANALYSIS OF WP1066
  • TABLE 60: LIST OF NEW ENTRANTS COMPETING TO EACH OTHER TO OCCUPY THE MARKET POTENTIAL IN 2031
  • TABLE 61: FACTORS CONSIDERED FOR R-NPV ANALYSIS OF WP1122
  • TABLE 62: LIST OF NEW ENTRANTS COMPETING TO EACH OTHER TO OCCUPY THE MARKET POTENTIAL IN 2032
  • TABLE 63: MARKET RESEARCH DATA ON APPROVED GLIOBLASTOMA MULTIFORME DRUGS (USD)
  • TABLE 64: ESTIMATED AVERAGE SELLING PRICES OF FILED AND LATE-CLINICAL STAGE GBM PIPELINE DRUGS
  • TABLE 65: PERCEIVED VALUE OF GLIOBLASTOMA MULTIFORME PRESCRIPTION DRUG BY COMPETITIVE BENCHMARKING
  • TABLE 66: COMPANIES LOOKING FOR IN-LICENSING OPPORTUNITIES V/S COMPANY TYPE
  • TABLE 67: COMPANIES LOOKING FOR OUT-LICENSING OPPORTUNITIES V/S COMPANY TYPE
  • TABLE 68: COMPANIES LOOKING FOR CORPORATE PARTNERING OPPORTUNITIES V/S COMPANY TYPE
  • TABLE 69: COMPANIES LOOKING FOR SEEKING INVESTMENT/FUNDING OPPORTUNITIES V/S COMPANY TYPE
  • TABLE 70: COMPANIES WHO DEVELOPING THE PIPELINE ASSETS ON THEIR OWN V/S COMPANY TYPE

LIST OF FIGURES

  • FIGURE 1: PATHOPHYSIOLOGY OF PRIMARY AND SECONDARY GLIOBLASTOMA MULTIFORME
  • FIGURE 2: WORLDWIDE PREVALENCE AND PREVALENCE RATE OF GBM 2010 TO 2035
  • FIGURE 3: WORLDWIDE INCIDENCE AND INCIDENCE RATE OF GBM 2010 TO 2035
  • FIGURE 4: UNITED STATES PREVALENCE AND PREVALENCE RATE OF GBM 2010 TO 2035
  • FIGURE 5: UNITED STATES INCIDENCE AND INCIDENCE RATE OF GBM 2010 TO 2035
  • FIGURE 6: EUROPE PREVALENCE AND PREVALENCE RATE (PER 100000) OF GBM FROM 2010 TO 2035
  • FIGURE 7: EUROPE INCIDENCE AND INCIDENCE RATE (PER 100000) OF GBM 2010 TO 2035
  • FIGURE 8: POLAND PREVALENCE AND PREVALENCE RATE (PER 100000) OF GBM CANCER FROM 2010 TO 2035
  • FIGURE 9: POLAND INCIDENCE AND INCIDENCE RATE (PER 100000) OF GBM FROM 2010 TO 2035
  • FIGURE 10: RUSSIA PREVALENCE AND PREVALENCE RATE (PER 100000) OF GBM CANCER FROM 2010 TO 2035
  • FIGURE 11: RUSSIA INCIDENCE AND INCIDENCE RATE (PER 100000) OF GBM FROM 2010 TO 2035
  • FIGURE 12: SWITZERLAND PREVALENCE AND PREVALENCE RATE (PER 100000) OF GBM FROM 2010 TO 2035
  • FIGURE 13: SWITZERLAND INCIDENCE AND INCIDENCE RATE (PER 100000) OF GBM 2010 TO 2035
  • FIGURE 14: SWEDEN PREVALENCE AND PREVALENCE RATE (PER 100000) OF GBM FROM 2010 TO 2035
  • FIGURE 15: SWEDEN INCIDENCE AND INCIDENCE RATE (PER 100000) OF GBM 2010 TO 2035
  • FIGURE 16: ITALY PREVALENCE AND PREVALENCE RATE (PER 100000) OF GBM FROM 2010 TO 2035
  • FIGURE 17: ITALY INCIDENCE AND INCIDENCE RATE (PER 100000) OF GBM 2010 TO 2035
  • FIGURE 18: GERMANY PREVALENCE AND PREVALENCE RATE (PER 100000) OF GBM FROM 2010 TO 2035
  • FIGURE 19: GERMANY INCIDENCE AND INCIDENCE RATE (PER 100000) OF GBM 2010 TO 2035
  • FIGURE 20: AUSTRIA PREVALENCE AND PREVALENCE RATE (PER 100000) OF GBM FROM 2010 TO 2035
  • FIGURE 21: AUSTRIA INCIDENCE AND INCIDENCE RATE (PER 100000) OF GBM 2010 TO 2035
  • FIGURE 22: FRANCE PREVALENCE AND PREVALENCE RATE (PER 100000) OF GBM FROM 2010 TO 2035
  • FIGURE 23: FRANCE INCIDENCE AND INCIDENCE RATE (PER 100000) OF GBM 2010 TO 2035
  • FIGURE 24: UNITED KINGDOM PREVALENCE AND PREVALENCE RATE (PER 100000) OF GBM FROM 2010 TO 2035
  • FIGURE 25: UNITED KINGDOM INCIDENCE AND INCIDENCE RATE (PER 100000) OF GBM 2010 TO 2035
  • FIGURE 26: CHINA PREVALENCE AND PREVALENCE RATE (PER 100000) OF GBM FROM 2010 TO 2035
  • FIGURE 27: CHINA INCIDENCE AND INCIDENCE RATE (PER 100000) OF GBM 2010 TO 2035
  • FIGURE 28: TREATMENT SERVED POPULATION & UNDIAGNOSED POPULATION (2020)
  • FIGURE 29: GBM UNDIAGNOSED POPULATION IN THE YEAR 2020
  • FIGURE 30: GLIOBLASTOMA MULTIFORME MARKET OPPORTUNITY
  • FIGURE 31: GBM CURRENT GLOBAL MARKET ANALYTICS (2020) AND FORECAST (2020-2035)
  • FIGURE 32: GBM CURRENT GLOBAL MARKET SNAPSHOT, 2020
  • FIGURE 33: GBM CURRENT GLOBAL MARKET (2020), SEGMENTATION BY ROA
  • FIGURE 34: GBM CURRENT GLOBAL MARKET (2020), SEGMENTATION BY MOLECULE TYPE
  • FIGURE 35: GBM GLOBAL MARKET (2020-2035), SEGMENTED BY EXISTING AVAILABLE GBM MARKET & NEW ENTRANTS MARKET
  • FIGURE 36: REALIZED AND UNREALIZED GLOBAL GBM MARKET IN 2021
  • FIGURE 37: TOTAL GBM MARKET IN 2022 SEGMENTED BY EXISTING MARKET AND NEW ENTRANTS MARKET
  • FIGURE 38: REALIZED AND UNREALIZED GLOBAL GBM MARKET IN 2022
  • FIGURE 39: TOTAL GBM MARKET IN 2023 SEGMENTED BY EXISTING MARKET AND NEW ENTRANTS MARKET
  • FIGURE 40: REALIZED AND UNREALIZED GLOBAL GBM MARKET IN 2023
  • FIGURE 41: TOTAL GBM MARKET IN 2024 SEGMENTED BY EXISTING MARKET AND NEW ENTRANTS MARKET
  • FIGURE 42: REALIZED AND UNREALIZED GLOBAL GBM MARKET IN 2024
  • FIGURE 43: TOTAL GBM MARKET IN 2025 SEGMENTED BY EXISTING MARKET AND NEW ENTRANTS MARKET
  • FIGURE 44: REALIZED AND UNREALIZED GLOBAL GBM MARKET IN 2025
  • FIGURE 45: TOTAL GBM MARKET IN 2026 SEGMENTED BY EXISTING MARKET AND NEW ENTRANTS MARKET
  • FIGURE 46: REALIZED AND UNREALIZED GLOBAL GBM MARKET IN 2026
  • FIGURE 47: TOTAL GBM MARKET IN 2027 SEGMENTED BY EXISTING MARKET AND NEW ENTRANTS MARKET
  • FIGURE 48: REALIZED AND UNREALIZED GLOBAL GBM MARKET IN 2027
  • FIGURE 49: TOTAL GBM MARKET IN 2028 SEGMENTED BY EXISTING MARKET AND NEW ENTRANTS MARKET
  • FIGURE 50: REALIZED AND UNREALIZED GLOBAL GBM MARKET IN 2028
  • FIGURE 51: TOTAL GBM MARKET IN 2029 SEGMENTED BY EXISTING MARKET AND NEW ENTRANTS MARKET
  • FIGURE 52: REALIZED AND UNREALIZED GLOBAL GBM MARKET IN 2029
  • FIGURE 53: TOTAL GBM MARKET IN 2030 SEGMENTED BY EXISTING MARKET AND NEW ENTRANTS MARKET
  • FIGURE 54: REALIZED AND UNREALIZED GLOBAL GBM MARKET IN 2030
  • FIGURE 55: REALIZED AND UNREALIZED GLOBAL GBM MARKET IN 2031
  • FIGURE 56: TOTAL GBM MARKET IN 2032 SEGMENTED BY EXISTING MARKET AND NEW ENTRANTS MARKET
  • FIGURE 57: REALIZED AND UNREALIZED GLOBAL GBM MARKET IN 2032
  • FIGURE 58: TOTAL GBM MARKET IN 2033 SEGMENTED BY EXISTING MARKET AND NEW ENTRANTS MARKET
  • FIGURE 59: REALIZED AND UNREALIZED WW GBM MARKET IN 2033
  • FIGURE 60: TOTAL GBM MARKET IN 2034 SEGMENTED BY EXISTING MARKET AND NEW ENTRANTS MARKET
  • FIGURE 61: REALIZED AND UNREALIZED GLOBAL GBM MARKET IN 2034
  • FIGURE 62: TOTAL GBM MARKET IN 2035 SEGMENTED BY EXISTING MARKET AND NEW ENTRANTS MARKET
  • FIGURE 63: REALIZED AND UNREALIZED GLOBAL GBM MARKET IN 2035
  • FIGURE 64: GBM GLOBAL MARKET FORECAST - 2035 BY ROA
  • FIGURE 65: GBM GLOBAL MARKET FORECAST - 2035 BY MOLECULE TYPE
  • FIGURE 66: UNITED STATES CURRENT (2020) GBM MARKET VALUE COMPARED WITH GLOBAL MARKET (M$)
  • FIGURE 67: UNITED STATES CURRENT (2020) AND FORECASTED (2035) GBM MARKET (M$)
  • FIGURE 68: YEAR BY YEAR COMPARISON OF GBM MARKET VALUES GLOBAL VS USA (2020 - 2035) (M$)
  • FIGURE 69: POLAND CURRENT (2020) GBM MARKET VALUE COMPARED WITH GLOBAL MARKET (M$)
  • FIGURE 70: POLAND CURRENT (2020) AND FORECASTED (2035) GBM MARKET (M$)
  • FIGURE 71: YEAR BY YEAR COMPARISON OF GBM MARKET VALUES GLOBAL VS POLAND (2020 - 2035) (M$)
  • FIGURE 72: RUSSIA CURRENT (2020) GBM MARKET VALUE COMPARED WITH GLOBAL MARKET (M$)
  • FIGURE 73: RUSSIA CURRENT (2020) AND FORECASTED (2035) GBM MARKET (M$)
  • FIGURE 74: YEAR BY YEAR COMPARISON OF GBM MARKET VALUES GLOBAL VS RUSSIA (2020 - 2035) (M$)
  • FIGURE 75: SWITZERLAND CURRENT (2020) GBM MARKET VALUE COMPARED WITH GLOBAL MARKET (M$)
  • FIGURE 76: SWITZERLAND CURRENT (2020) AND FORECASTED (2035) GBM MARKET (M$)
  • FIGURE 77: YEAR BY YEAR COMPARISON OF GBM MARKET VALUES GLOBAL VS SWITZERLAND (2020 - 2035) (M$)
  • FIGURE 78: SWEDEN CURRENT (2020) GBM MARKET VALUE COMPARED WITH GLOBAL MARKET (M$)
  • FIGURE 79: SWEDEN CURRENT (2020) AND FORECASTED (2035) GBM MARKET (M$)
  • FIGURE 80: YEAR BY YEAR COMPARISON OF GBM MARKET VALUES GLOBAL VS SWEDEN (2020 - 2035) (M$)
  • FIGURE 81: ITALY CURRENT (2020) GBM MARKET VALUE COMPARED WITH GLOBAL MARKET (M$)
  • FIGURE 82: ITALY CURRENT (2020) AND FORECASTED (2035) GBM MARKET (M$)
  • FIGURE 83: YEAR BY YEAR COMPARISON OF GBM MARKET VALUES GLOBAL VS ITALY (2020 - 2035) (M$)
  • FIGURE 84: GERMANY CURRENT (2020) GBM MARKET VALUE COMPARED WITH GLOBAL MARKET (M$)
  • FIGURE 85: GERMANY CURRENT (2020) AND FORECASTED (2035) GBM MARKET (M$)
  • FIGURE 86: YEAR BY YEAR COMPARISON OF GBM MARKET VALUES GLOBAL VS GERMANY (2020 - 2035) (M$)
  • FIGURE 87: AUSTRIA CURRENT (2020) GBM MARKET VALUE COMPARED WITH GLOBAL MARKET (M$)
  • FIGURE 88: AUSTRIA CURRENT (2020) AND FORECASTED (2035) GBM MARKET (M$)
  • FIGURE 89: YEAR BY YEAR COMPARISON OF GBM MARKET VALUES GLOBAL VS AUSTRIA (2020 - 2035) (M$)
  • FIGURE 90: FRANCE CURRENT (2020) GBM MARKET VALUE COMPARED WITH GLOBAL MARKET (M$)
  • FIGURE 91: FRANCE CURRENT (2020) AND FORECASTED (2035) GBM MARKET (M$)
  • FIGURE 92: YEAR BY YEAR COMPARISON OF GBM MARKET VALUES GLOBAL VS FRANCE (2020 - 2035) (M$)
  • FIGURE 93: UNITED KINGDOM CURRENT (2020) GBM MARKET VALUE COMPARED WITH GLOBAL MARKET (M$)
  • FIGURE 94: UNITED KINGDOM CURRENT (2020) AND FORECASTED (2035) GBM MARKET (M$)
  • FIGURE 95: YEAR BY YEAR COMPARISON OF GBM MARKET VALUES GLOBAL VS UNITED KINGDOM (2020 - 2035) (M$)
  • FIGURE 96: CHINA CURRENT (2020) GBM MARKET VALUE COMPARED WITH GLOBAL MARKET (M$)
  • FIGURE 97: CHINA CURRENT (2020) AND FORECASTED (2035) GBM MARKET (M$)
  • FIGURE 98: YEAR BY YEAR COMPARISON OF GBM MARKET VALUES GLOBAL VS CHINA (2020 - 2035) (M$)
  • FIGURE 99: UNMET NEEDS & CHALLENGES TO DRUG DELIVERY
  • FIGURE 100: SCHEMATIC REPRESENTATION OF UNMET NEEDS & OPPORTUNITIES FOR GEOGRAPHY
  • FIGURE 101: GBM DRUG PIPELINE ANALYTICS BY STAGE OF DEVELOPMENT
  • FIGURE 102: GRAPHICAL REPRESENTATION OF GBM PIPELINE DRUGS FOR EXPECTED APPROVAL REGIONS AND HSD
  • FIGURE 103: GBM DRUG PIPELINE ANALYTICS BY STAGE OF DEVELOPMENT
  • FIGURE 104: GBM DEAL ANALYTICS BY DEAL TYPE
  • FIGURE 105: BREAKDOWN OF DEAL EXPECTATIONS UNDER COLLABORATION AGREEMENTS
  • FIGURE 106: BREAKDOWN OF DEAL EXPECTATIONS UNDER LICENSING AGREEMENTS
  • FIGURE 107: BREAKDOWN OF DEAL EXPECTATIONS UNDER FINANCING DEALS
  • FIGURE 108: BREAKDOWN OF DEAL EXPECTATIONS UNDER M&A DEALS
  • FIGURE 109: GBM DEAL ANALYTICS BY ANNUAL DEAL FREQUENCY
  • FIGURE 110: DEAL TYPE BREAKDOWN FOR THE YEAR OF 2020
  • FIGURE 111: COMPARATIVE PATENT ANTICIPATED EXPIRIES OF OTHER PIPELINE DRUGS COMPARED WITH WPD101
  • FIGURE 112: COMPARATIVE PATENT ANTICIPATED EXPIRIES OF OTHER PIPELINE DRUGS COMPARED WITH BERUBICIN
  • FIGURE 113: COMPARATIVE PATENT ANTICIPATED EXPIRIES OF OTHER PIPELINE DRUGS COMPARED WITH WP1066
  • FIGURE 114: COMPARATIVE PATENT ANTICIPATED EXPIRIES OF OTHER PIPELINE DRUGS COMPARED WITH WP1122
  • FIGURE 115: WORLDWIDE ESTIMATED SALES POTENTIAL OF WPD101 IN MILLION USD
  • FIGURE 116: UNITED STATES ESTIMATED SALES POTENTIAL OF WPD101 IN MILLION USD
  • FIGURE 117: POLAND'S ESTIMATED SALES POTENTIAL OF WPD101 IN MILLION USD
  • FIGURE 118: RUSSIA'S ESTIMATED SALES POTENTIAL OF WPD101 IN MILLION USD
  • FIGURE 119: SWITZERLAND'S ESTIMATED SALES POTENTIAL OF WPD101 IN MILLION USD
  • FIGURE 120: SWEDEN'S ESTIMATED SALES POTENTIAL OF WPD101 IN MILLION USD
  • FIGURE 121: ITALY'S ESTIMATED SALES POTENTIAL OF WPD101 IN MILLION USD
  • FIGURE 122: GERMANY'S ESTIMATED SALES POTENTIAL OF WPD101 IN MILLION USD
  • FIGURE 123: AUSTRIA'S ESTIMATED SALES POTENTIAL OF WPD101 IN MILLION USD
  • FIGURE 124: FRANCE'S ESTIMATED SALES POTENTIAL OF WPD101 IN MILLION USD
  • FIGURE 125: UNITED KINGDOM'S ESTIMATED SALES POTENTIAL OF WPD101 IN MILLION USD
  • FIGURE 126: CHINA'S ESTIMATED SALES POTENTIAL OF WPD101 IN MILLION USD
  • FIGURE 127: COMPARISON SNAPSHOT OF WPD101 MARKET VALUES IN MILLION USD - GLOBAL VS EU9, CHINA AND US
  • FIGURE 128: WORLDWIDE ESTIMATED SALES POTENTIAL OF BERUBICIN IN MILLION USD
  • FIGURE 129: POLAND'S ESTIMATED SALES POTENTIAL OF BERUBICIN IN MILLION USD
  • FIGURE 130: RUSSIA'S ESTIMATED SALES POTENTIAL OF BERUBICIN IN MILLION USD
  • FIGURE 131: AUSTRIA'S ESTIMATED SALES POTENTIAL OF BERUBICIN IN MILLION USD
  • FIGURE 132: COMPARISON SNAPSHOT OF BERUBICIN MARKET VALUES IN MILLION USD - GLOBAL VS EU3 COUNTRIES
  • FIGURE 133: WORLDWIDE ESTIMATED SALES POTENTIAL OF WP1066 IN MILLION USD
  • FIGURE 134: POLAND'S ESTIMATED SALES POTENTIAL OF WP1066 IN MILLION USD
  • FIGURE 135: SWEDEN'S ESTIMATED SALES POTENTIAL OF WP1066 IN MILLION USD
  • FIGURE 136: SWITZERLAND'S ESTIMATED SALES POTENTIAL OF WP1066 IN MILLION USD
  • FIGURE 137: COMPARISON SNAPSHOT OF WP1066 MARKET VALUES IN MILLION USD - GLOBAL VS EU3 COUNTRIES
  • FIGURE 138: WORLDWIDE ESTIMATED SALES POTENTIAL OF WP1122 IN MILLION USD
  • FIGURE 139: POLAND'S ESTIMATED SALES POTENTIAL OF WP1122 IN MILLION USD
  • FIGURE 140: SWEDEN'S ESTIMATED SALES POTENTIAL OF WP1122 IN MILLION USD
  • FIGURE 141: SWITZERLAND'S ESTIMATED SALES POTENTIAL OF WP1122 IN MILLION USD
  • FIGURE 142: COMPARISON SNAPSHOT OF WP1122 MARKET VALUES IN MILLION USD - GLOBAL VS EU3 COUNTRIES
  • FIGURE 143: COMPANY TYPE ANALYTICS BY OPPORTUNITY ASSESSMENTS
  • FIGURE 144: COMPANY TYPE VS OPPORTUNITY ASSESSMENTS
  • FIGURE 145: COMPANY TYPE ANALYTICS BY LICENSING OPPORTUNITIES
  • FIGURE 146: COMPANIES WHO DEVELOPING THEIR PIPELINE ASSETS ON THEIR OWN V/S COMPANY TYPE